Citigroup Maintains Buy on Structure Therapeutics, Lowers Price Target to $97

Benzinga Newsdesk www.benzinga.com Neutral 64.1%

Neg 0% Neu 64.1% Pos 0%

Citigroup analyst Samantha Semenkow maintains Structure Therapeutics (NASDAQ:GPCR) with a Buy and lowers the price target from $100 to $97.